Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02771301Not ApplicableUnknown

Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas

Role: lead

NCT02416999Not ApplicableUnknown

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Role: lead

NCT02333513Not ApplicableUnknown

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Role: lead

All 3 trials loaded